Commentary: Hyperreflective foci on optical coherence tomography and their clinical implications in diabetic macular edema

Autor: Kumar Saurabh, Suraj Mistry, Rupak Roy, Sujay Herekar, Shruti Choudhari
Rok vydání: 2021
Předmět:
medicine.medical_specialty
Visual acuity
retinal hyperreflective foci
genetic structures
Diabetic macular edema
Visual Acuity
Angiogenesis Inhibitors
Pilot Projects
Macular Edema
Retina
Group B
chemistry.chemical_compound
Optical coherence tomography
Pro re nata
Statistical significance
Ophthalmology
Diabetes Mellitus
Humans
Medicine
Prospective Studies
External limiting membrane
Choroidal hyperreflective foci
Retrospective Studies
Diabetic Retinopathy
medicine.diagnostic_test
business.industry
Retinal
Diabetic retinopathy
Middle Aged
medicine.disease
eye diseases
Hyperreflective foci
Regimen
medicine.anatomical_structure
chemistry
spectral-domain optical coherence tomography
Intravitreal Injections
Commentary
Original Article
sense organs
medicine.symptom
diabetic macular edema
business
Tomography
Optical Coherence
Zdroj: Indian Journal of Ophthalmology
ISSN: 0301-4738
DOI: 10.4103/ijo.ijo_2530_21
Popis: Purpose Choroidal hyperreflective foci (HCF) are novel spectral-domain optical coherence tomography (SDOCT) biomarkers in diabetic macular edema (DME). The present study intended to validate HCF and assess their role in the treatment outcome. Methods It was a retrospective, longitudinal, records-based pilot study recruiting consecutive patients of nonproliferative diabetic retinopathy with treatment naive DME. Patients were treated with three intravitreal anti-vascular endothelial growth factor injections and followed by a pro re nata regimen. Results A total of 43 eyes of 28 patients were included in the study. Eyes were divided into two groups. Group A (n = 19) comprised eyes with retinal hyperreflective foci (HRF) and group B (n = 24) had eyes with both HRF and HCF. The mean age of patients in group A and B was 58.5 ± 2.1 years and 55.2 ± 8.8 years, respectively. Mean best-corrected visual acuity at presentation was 0.38 ± 0.25 in group A and 0.59 ± 0.29 in group B (P = 0.01). Final BCVA was 0.35 ± 0.39 in group A and 0.47 ± 0.34 in group B (P = 0.3). External limiting membrane was intact in 19 out of 19 eyes in group A and two (8.3%) eyes in group B (P = 0). Conclusion Presence of HCF meant significantly worse initial BCVA compared to the eye that had HRF alone. The final BCVA was also worse in eyes with HCF compared to those with HRF and without HCF; however, the difference did not reach a significance level, probably pointing toward the fact that HCF and HRF are pathophysiologically identical. Further studies with a larger sample size and prospective design are needed to take these findings forward.
Databáze: OpenAIRE
Externí odkaz: